A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Clinical trial NCT05415215 · COMPLETED

Trial details

NCT number: NCT05415215
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Early Breast Cancer Locally Advanced Breast Cancer Inflammatory Breast Cancer

Start date: 2022-07-05
Primary completion: 2024-11-20
Enrollment: 346

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.